Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

59.88
-0.4800-0.80%
Post-market: 59.880.00000.00%19:30 EDT
Volume:1.87M
Turnover:112.59M
Market Cap:9.95B
PE:-17.21
High:60.99
Open:60.37
Low:59.78
Close:60.36
52wk High:86.74
52wk Low:49.13
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.93
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:22.63
PE(LYR):-25.15

Loading ...

RBC Lifts Price Target on Ionis Pharmaceuticals to $100 From $95, Keeps Outperform Rating

MT Newswires Live
·
Apr 30

Ionis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 30

Ionis Pharmaceuticals price target raised to $125 from $120 at H.C. Wainwright

TIPRANKS
·
Apr 30

Ionis Pharmaceuticals Inc : H.c. Wainwright Raises Target Price to $125 From $120

THOMSON REUTERS
·
Apr 30

Ionis Pharmaceuticals’ Earnings Call Flags Growth and Risks

TIPRANKS
·
Apr 30

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Viking Therapeutics (VKTX)

TIPRANKS
·
Apr 30

Analyst Reiterates Buy Rating on Ionis Pharmaceuticals, Maintains $105 Price Target on Strong Q1 and Upgraded Olezarsen Outlook

TIPRANKS
·
Apr 30

Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c)

TIPRANKS
·
Apr 29

Ionis Pharmaceuticals raises FY26 revenue view $875M-$900M from $800M-$825M

TIPRANKS
·
Apr 29

Ionis Q1 revenue rises 87% on R&D payments boost

Reuters
·
Apr 29

Ionis Q1 FY26 net loss narrows 37% to $93 million; revenue rises 87% to $246 million

Reuters
·
Apr 29

GUIDANCE: (IONS) Ionis Pharmaceuticals Expects 2026 Total Revenue Range $875M - $900M, vs. FactSet Est of $808.5M

MT Newswires Live
·
Apr 29

Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q1 Loss $0.56 a Share, vs. FactSet Est of $0.88 Loss

MT Newswires Live
·
Apr 29

Ionis Pharmaceuticals Q1 Adj. EPS $(0.30) Beats $(0.91) Estimate, Sales $246.000M Beat $195.628M Estimate

Benzinga Earnings
·
Apr 29

Ionis Reports First Quarter 2026 Financial Results and Highlights Progress on Key Programs

THOMSON REUTERS
·
Apr 29

Ionis Pharmaceuticals Inc - Lowers 2026 Non-Gaap Operating Loss Guidance to $425-$475 Mln From $500-$550 Mln

THOMSON REUTERS
·
Apr 29

Ionis Pharmaceuticals Q1 Revenue USD 43 Million VS. Ibes Estimate USD 195.6 Million

THOMSON REUTERS
·
Apr 29

Ionis Pharmaceuticals Q1 Operating Income USD -118 Million

THOMSON REUTERS
·
Apr 29

Ionis Pharmaceuticals Outlook FY Revenue USD 875-900 Million

THOMSON REUTERS
·
Apr 29

Ionis Pharmaceuticals Inc - Raises 2026 Total Revenue Guidance to $875-$900 Mln From $800-$825 Mln

THOMSON REUTERS
·
Apr 29